- Report
- January 2025
- 182 Pages
Global
From €4006EUR$4,500USD£3,500GBP
- Report
- January 2025
- 180 Pages
Global
From €4006EUR$4,500USD£3,500GBP
- Report
- June 2025
- 150 Pages
Global
From €3427EUR$3,850USD£2,995GBP
€4318EUR$4,850USD£3,773GBP
- Report
- June 2025
- 200 Pages
Global
From €2483EUR$2,789USD£2,169GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2483EUR$2,789USD£2,169GBP
- Report
- June 2025
- 400 Pages
Global
From €4406EUR$4,949USD£3,850GBP
- Report
- October 2023
- 157 Pages
Global
From €4139EUR$4,650USD£3,617GBP
- Report
- April 2023
- 275 Pages
Global
From €3552EUR$3,990USD£3,104GBP
- Report
- March 2024
- 200 Pages
Global
From €3694EUR$4,150USD£3,228GBP
- Report
- October 2024
- 244 Pages
Global
From €5662EUR$6,360USD£4,947GBP
€7077EUR$7,950USD£6,184GBP
- Report
- April 2023
- 110 Pages
Global
From €4228EUR$4,750USD£3,695GBP
- Report
- April 2023
- 120 Pages
Global
From €4228EUR$4,750USD£3,695GBP
- Report
- April 2023
- 129 Pages
Global
From €4228EUR$4,750USD£3,695GBP
- Report
- May 2024
- 128 Pages
Global
From €4918EUR$5,524USD£4,297GBP
€5785EUR$6,499USD£5,055GBP
- Report
- May 2024
- 136 Pages
Global
From €4918EUR$5,524USD£4,297GBP
€5785EUR$6,499USD£5,055GBP
- Report
- May 2024
- 136 Pages
Global
From €4918EUR$5,524USD£4,297GBP
€5785EUR$6,499USD£5,055GBP
- Report
- September 2023
- 143 Pages
Middle East, Africa
From €1335EUR$1,500USD£1,167GBP
- Report
- September 2023
- 128 Pages
North America
From €1335EUR$1,500USD£1,167GBP
- Report
- July 2023
- 298 Pages
Global
From €3205EUR$3,600USD£2,800GBP
- Report
- July 2023
- 141 Pages
Asia Pacific
From €1335EUR$1,500USD£1,167GBP

The Antiplatelet Drugs market within the context of Cardiovascular Drugs is a rapidly growing sector of the pharmaceutical industry. Antiplatelet drugs are used to reduce the risk of heart attack and stroke by preventing the formation of blood clots. These drugs are used to treat a variety of cardiovascular conditions, including coronary artery disease, peripheral artery disease, and atrial fibrillation. Commonly prescribed antiplatelet drugs include aspirin, clopidogrel, ticagrelor, and prasugrel.
These drugs are typically taken orally, and are often prescribed in combination with other medications. In addition to reducing the risk of heart attack and stroke, antiplatelet drugs can also reduce the risk of other cardiovascular complications, such as deep vein thrombosis and pulmonary embolism.
Some of the major companies in the Antiplatelet Drugs market include Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more